4D Molecular Therapeutics (FDMT) Asset Utilization Ratio (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Asset Utilization Ratio data on file, last reported at 0.16 in Q1 2026.

• Asset Utilization Ratio for Q1 2026 came in at 0.16, up 382316.02% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.16 (up 382316.02% YoY), and the FY2025 annual result was 0.15, up 183849.42% from the prior year.
• Asset Utilization Ratio slipped to 0.16 in Q1 2026 per FDMT's latest filing, from 0.17 in the prior quarter.
• Over five years, Asset Utilization Ratio peaked at 0.17 in Q4 2025 and troughed at 0.0 in Q3 2024.
• A 5-year average of 0.04 and a median of 0.01 in 2022 frame the typical range for Asset Utilization Ratio.
• The sharpest annual moves came in 2024 and 2026: Asset Utilization Ratio tumbled 99.95% in 2024, then soared 382316.02% in 2026.
• A 5-year view of Asset Utilization Ratio shows it stood at 0.01 in 2022, then soared by 411.85% to 0.06 in 2023, then tumbled by 99.89% to 0.0 in 2024, then surged by 270576.98% to 0.17 in 2025, then declined by 4.97% to 0.16 in 2026.
• Business Quant data shows FDMT's Asset Utilization Ratio at 0.16 in Q1 2026, 0.17 in Q4 2025, and 0.0 in Q3 2025.